A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Moderna, Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 22,673 shares of MRNA stock, worth $835,500. This represents 0.02% of its overall portfolio holdings.

Number of Shares
22,673
Previous 18,444 22.93%
Holding current value
$835,500
Previous $2.19 Million 30.82%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$63.64 - $125.14 $269,133 - $529,217
4,229 Added 22.93%
22,673 $1.52 Million
Q2 2024

Aug 13, 2024

BUY
$101.21 - $166.61 $246,142 - $405,195
2,432 Added 15.19%
18,444 $2.19 Million
Q1 2024

May 15, 2024

BUY
$85.37 - $115.44 $141,116 - $190,822
1,653 Added 11.51%
16,012 $1.71 Million
Q4 2023

Feb 13, 2024

SELL
$69.51 - $104.43 $20,088 - $30,180
-289 Reduced 1.97%
14,359 $1.43 Million
Q3 2023

Nov 13, 2023

BUY
$96.41 - $126.61 $601,791 - $790,299
6,242 Added 74.26%
14,648 $1.51 Million
Q2 2023

Aug 11, 2023

BUY
$118.5 - $160.53 $76,551 - $103,702
646 Added 8.32%
8,406 $1.02 Million
Q1 2023

May 10, 2023

SELL
$135.66 - $197.02 $128,605 - $186,774
-948 Reduced 10.89%
7,760 $1.19 Million
Q4 2022

Feb 13, 2023

SELL
$118.38 - $210.04 $62,031 - $110,060
-524 Reduced 5.68%
8,708 $1.56 Million
Q3 2022

Nov 14, 2022

BUY
$118.07 - $194.18 $82,412 - $135,537
698 Added 8.18%
9,232 $1.09 Million
Q2 2022

Aug 12, 2022

SELL
$117.13 - $176.59 $357,832 - $539,482
-3,055 Reduced 26.36%
8,534 $1.22 Million
Q1 2022

May 10, 2022

SELL
$126.46 - $235.05 $37,938 - $70,515
-300 Reduced 2.52%
11,589 $2 Million
Q4 2021

Feb 11, 2022

BUY
$225.82 - $368.51 $2.68 Million - $4.38 Million
11,889 New
11,889 $2.99 Million

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $14.4B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track B. Metzler Seel. Sohn & Co. Ag Portfolio

Follow B. Metzler Seel. Sohn & Co. Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of B. Metzler Seel. Sohn & Co. Ag, based on Form 13F filings with the SEC.

News

Stay updated on B. Metzler Seel. Sohn & Co. Ag with notifications on news.